Energenesis Biomedical, founded in 2012, is a biotech company publicly listed on the Taiwan Stock Exchange Corporation (TWSE: 6657) in 2023. With over a decade of commitment, our team has pioneered the ENERGI-Platform, a novel approach using small molecule drugs to boost cellular energy levels. This technology activates self-healing mechanisms within cells, empowering us to explore innovative ways of addressing challenging diseases.

Pipeline:

ENERGI-F703DFU: gel for Diabetic foot ulcers (Phase III, recruiting in the US and Taiwan)

ENERGI-F701: hair tonic for Alopecia (Phase II, completed)

ENERGI-F703EB: cream for Epidermolysis Bullosa (in preparation for Phase II, granted ODD&RPD)

ENERGI-F705PD : oral medicine for Parkinson’s disease (in preparation for Phase II)

Energenesis Biomedical

STEVEN

This department focuses on identifying growth opportunities, forming strategic partnerships, and expanding market reach.

Business Development

This department oversees organizational strategies and ensures operational efficiency.

Management

This department focuses on bridging the gap between laboratory research and clinical applications to improve patient outcomes.

Energenesis Biomedical

Org chart

Teams

Business Development

Management

Translational Medicine

Offices

Energenesis Biomedical

Org chart

Teams

Business Development

Management

Translational Medicine

Offices

Related companies